Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis

A J Lucking, A Visvanathan, H Philippou, S Fraser, P J Grant, T M Connolly, S J Gardell, G Z Feuerstein, K A A Fox, N A Booth, D E Newby

Research output: Contribution to journalArticlepeer-review

Abstract

The principal inhibitor of fibrinolysis in vivo is plasminogen activator inhibitor-1 (PAI-1). PAI-749 is a small molecule inhibitor of PAI-1 with proven antithrombotic efficacy in several preclinical models.
Original languageEnglish
Pages (from-to)1333-9
Number of pages7
JournalJournal of Thrombosis and Haemostasis
Volume8
Issue number6
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis'. Together they form a unique fingerprint.

Cite this